Sulforaphane (SFN) is produced when the enzyme myrosinase transforms glucoraphanin upon damage to the plant such as from chewing and effective in preventing carcinogenesis, diabetes, and inflammatory responses. Transforming growth factor -induced protein (TGFBIp) is an extracellular matrix protein whose expression in several cell types is greatly increased by TGF-TGFBIp is released by human umbilical vein endothelial cells (HUVECs) and functions as a mediator of experimental sepsis. We hypothesized that SFN could reduce TGFBIp-mediated severe inflammatory responses in human endothelial cells and mice. Here, we investigated the anti-septic effects and underlying mechanisms of SFN against TGFBIp-mediated septic responses. SFN effectively inhibited lipopolysaccharide-induced release of TGFBIp and suppressed TGFBIp-mediated septic responses. In addition, SFN suppressed cecal ligation and puncture (CLP)-induced sepsis lethality and pulmonary injury. In conclusion, SFN suppressed TGFBIp-mediated and CLP-induced septic responses. Therefore, SFN could be a potential therapeutic agent for treatment of various severe vascular inflammatory diseases via inhibition of the TGFBIp signaling pathway.
Transforming growth factor -induced protein (TGFBIp) is an extracellular matrix protein that can be highly expressed in various cell types [1] [2] [3] . TGFBIp contains an N-terminal secretory signal peptide, followed by a cysteine-rich domain, four internal homologous repeats (FAS1 domain), and a C-terminal tripeptideArg-Gly-Asp (RGD) motif [1] . Several studies suggest that TGFBIp is involved in cell growth, cell differentiation, wound healing, tumorigenesis, and apoptosis [2] [3] [4] . Recently, we reported that TGFBIp is a promising therapeutic target for the treatment of sepsis and septic shock [3, 5] . In fact, blocking TGFBIp, even at later times after the onset of infection, has been shown to rescue mice from lethal sepsis [5] . TGFBIp also acts as a lethal mediator in conditions such as sepsis, in which serum TGFBIp levels are substantially increased [3, 5] . Once released into the extracellular milieu, TGFBIp can bind to cell surface receptors, such as integrinsv3 and v5, in human endothelial cells [6] . Sulforaphane (SFN is produced when the enzyme myrosinase transforms glucoraphanin upon damage to the plant such as from chewing and exhibits anticancer and anti-diabetic properties in experimental models. SFN is a natural isothiocyanate present in cruciferous vegetables such as broccoli and cabbage [7] . Therefore, increased consumption of cruciferous vegetables has been associated with a decreased risk of several degenerative and chronic diseases, including cardiovascular disease. SFN has garnered particular interest as an indirect antioxidant due to its extraordinary ability to induce the expression of multiple endogenous enzymes via the upregulation of nuclear factor E2-related factor-2 (Nrf2) function [7] . In addition, Heiss et al. reported that SFN possesses anti-inflammatory properties, resulting in the downregulation of LPS-stimulated inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2 and tumor necrosis factor (TNF)expression in RAW macrophages due to the inhibition of DNA binding in NF-B [8] . Based on previous reports, which demonstrated the potential effects of TGFBIp on vascular inflammatory responses [3, 5] and anti-inflammatory activities of SFN [8] , we hypothesized that treatment with SFN would suppress TGFBIp-or cecal ligation and puncture (CLP)-induced septic responses in human endothelial cells and mice. The in vitro experimental design with exposure of human umbilical vein endothelial cells (HUVECs) to lipopolysaccharide (LPS) enables us to determine the effects of SFN on the secretion of TGFBIp protein and expression of TGFBIp mRNA and its receptors (integrin v3 and v5). To investigate the anti-septic effects of SFN in TGFBIpmediated septic responses, the following experimental techniques were used: hyperpermeability assessment, assessing expression of cell adhesion molecules (CAMs), and determining adhesion and migration of leukocytes to HUVECs. For the in vivo assessment, CLP-induced septic mice were used, because this model more closely resembles human sepsis [9] . In the CLP-induced septic model, we also tested the effects of SFN on lethality and pulmonary injury.
Our previous study demonstrated that stimulation of TGFBIp release by LPS from human endothelial cells and 100 ng/mL LPS is sufficient to induce release of TGFBIp [5] [6] . Similarly, in the current study, 100 ng/mL LPS stimulated the release of TGFBIp by HUVECs ( Figure 1A ). To investigate the effects of SFN on LPSmediated release of TGFBIp, HUVECs were stimulated with 100 ng/mL LPS for 1 h, followed by treatment with increasing concentrations of SFN for 6 h. As shown in Figure 1A , SFN inhibited the release of TGFBIp in HUVECs, with an optimal effective concentration > 10 M. In order to confirm these effects in vivo, CLP-induced septic mice were used, because this model more closely resembles human sepsis than LPS-induced endotoxemia [9] . As shown in Figure 1B , treatment with SFN resulted in marked inhibition of CLP-induced release of TGFBIp. The average circulating blood volume for mice is 72 mL/kg [10] . Because the average weight of used mice was 27 g and the average blood volume was 2 mL, the amount of SFN (0.26 or 0.39 mg/kg) injected yielded a maximum concentration of 20 or 30 M in the peripheral blood.
To determine the molecular mechanism by which SFN inhibited the release of LPS-mediated TGFBIp, we tested the effects of SFN on the transcriptional regulation of TGFBIp by LPS in HUVECs. Thus, we measured the effect of SFN on LPS-induced TGFBIp mRNA levels using real-time qRT-PCR. As shown in Figure 1C , LPS induced an increase in the expression levels of TGFBIp mRNA and treatment with SFN resulted in decreased expression levels of LPSinduced TGFBIp mRNA. Next, we investigated the effects of SFN on expression of the TGFBIp receptors, integrinsv3 and v5, in HUVECs [6] . As shown in Figure 1D , treatment with LPS resulted in an over four fold increase in expression of v5 in HUVECs, and treatment with SFN resulted in significantly inhibited expression of v5. However, consistent with previous findings [6] , the expression of integrin v3 was not changed by LPS [6] nor SFN ( Figure 1D ). Therefore, the inhibitory effects of SFN on the release of TGFBIp were mediated by suppression of TGFBIp receptor (integrin v5). High plasma concentrations of TGFBIp in patients with sepsis are known to be related to the severity of sepsis [6] , and pharmacological inhibition of TGFBIp is known to improve survival in animal models of sepsis [5] . Therefore, prevention of CLP-induced release of TGFBIp by SFN suggests the potential for use of SFN in the treatment of vascular inflammatory diseases.
A permeability assay was performed to determine the effects of SFN on the barrier integrity of HUVECs. Treatment with 50 M SFN alone did not alter barrier integrity (Figure 2A ). In contrast, TGFBIp is known to cause cleavage and disruption of endothelial barrier integrity [5] [6] . Thus, HUVECs were treated with various concentrations of SFN for 6 h after the addition of TGFBIp (5 g/mL). As shown in Figure 2A , treatment with SFN resulted in a dose-dependent decrease in TGFBIp-mediated disruption of barrier integrity. TGFBIp-mediated vascular permeability in mice was assessed in order to confirm this vascular barrier protective effect in vivo. As shown in Figure 2B , treatment with SFN resulted in markedly inhibited peritoneal leakage of dye induced by TGFBIp. Sepsis inducers, such as high mobility group box 1 (HMGB1) and LPS, are known to induce pro-inflammatory responses by promoting phosphorylation of p38 MAPK [11] [12] [13] [14] [15] . Therefore, we determined whether TGFBIp could also enhance the phosphorylation of p38 MAPK, and if so, whether SFN inhibited TGFBIp-induced activation of p38 MAPK in HUVECs. As shown in Figure 2C , TGFBIp induced the activation of p38 MAPK, which Figure 2D ).
Sepsis is a systemic response to serious infection and has a poor prognosis when it is associated with organ dysfunction, hypoperfusion, or hypotension [15] [16] . Based on the abovedescribed findings, we hypothesized that treatment with SFN would result in reduced mortality in our CLP-induced sepsis mouse model. To investigate the question of whether SFN protects mice from CLP-induced sepsis lethality, SFN was administered to mice after CLP. Twenty-four hours after the operation, animals manifested signs of sepsis such as shivering, bristled hair, and weakness. Administration of SFN (0.26 or 0.39 mg/kg, once 12 h after CLP and once 50 h after CLP) resulted in an increase in the survival rate from 40 to 60%, according to the Kaplan-Meier survival analysis (p < 0.0001, Figure 3A ). This marked survival benefit achieved by administration of SFN suggests that suppression of TGFBIp release and of TGFBIp-mediated inflammatory responses provides a therapeutic strategy for management of sepsis and septic shock. To confirm the protective effects of SFN on CLP-induced death, we determined the effects of SFN on CLP-induced pulmonary injury. There were no significant differences between lungs of sham and sham + SFN in light microscopic observations (data not shown). In the CLP group, the pulmonary architecture was severely damaged ( Figure 3B ). These morphological changes were less pronounced in the CLP + SFN group ( Figure 3B ).
In this study, we tested the hypothesis that treatment with SFN would suppress TGFBIp-or CLP-induced septic responses in human endothelial cells and mice. The results showed that SFN suppressed LPS-induced secretion and mRNA expression of TGFBIp or CLP-induced TGFBIp secretion. SFN also inhibited TGFBIp-mediated hyperpermeability and activation of p38. Finally, SFN protected against CLP-induced lethality and lung damage.
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Natural Product Communications Vol. 12 (10) 2017 1629 Therefore, the data are in accordance with our hypothesis that SFN can protect against TGFBIp-or CLP-induced septic responses in human endothelial cells and mice. The molecular mechanism of the anti-inflammatory effects of SFN against the TGFBIp-mediated septic response may be mediated by the suppression of TGFBIp release and transcriptional suppression of TGFBIp mRNA ( Figure  1A-1C ), the expressions of TGFBIp receptor (integrin v5, Figure  1D ), and TGFBIp-mediated hyperpermeability (Figure 2A, 2B) via suppression of the activation of p38 ( Figure 2C ). The possible main target of SFN in TGFBIp-mediated septic response could be the interactions between released TGFBIp and its receptor (integrin v5), because the binding of the ligand (TGFBIp) to its receptor (v5) mediated severe vascular inflammatory responses downstream such as hyperpermeabililty, adhesion, and migration of leukocytes toward endothelial cells [5] [6] . Based on the current findings, SFN has potential as a therapeutic agent for severe vascular inflammatory diseases, such as sepsis and septic shock.
Experimental
Reagents: SFN, evans blue and crystal violet were obtained from Sigma (St. Louis, MO). VybrantDiD (used at 5 M) was obtained from Invitrogen (Carlsbad, CA). TGFBIp protein was purified as described previously [6] .
Cell culture: Primary HUVECs were obtained from Cambrex Bio Science (Charles City, IA) and maintained as described previously [17] [18] . All experiments were carried out with HUVECs at passage 3-5. Human neutrophils were freshly isolated from whole blood (15 mL) obtained by venipuncture from five healthy volunteers and maintained as previously described [18] . The study protocol (KNUH 2012-01-010) was approved by the IRB of Kyungpook National University Hospitals (Daegu, Republic of Korea).
Animals and husbandry:
Male C57BL/6 mice (6-7 weeks old, weighing 27 g), purchased from Orient Bio Co. (Sungnam, Republic of Korea), were maintained as described previously [17] [18] .All animals were treated in accordance with the 'Guidelines for the Care and Use of Laboratory Animals' issued by Kyungpook National University (IRB No. KNU 2016-54).
CLP: For induction of sepsis, male mice were anesthetized with 2% isoflurane (Forane, JW pharmaceutical, South Korea) in oxygen delivered via a small rodent gas anesthesia machine (RC2, Vetequip, Pleasanton, CA), first in a breathing chamber and then via a facemask. They were allowed to breath spontaneously during the procedure. The CLP-induced sepsis model was prepared as previously described [6] . This protocol was approved by the Animal Care Committee at Kyungpook National University prior to conducting the study (IRB No. KNU 2016-54).
Cell viability assay:
MTT was used as an indicator of cell viability as previously described [17] . Cells were grown in 96-well plates at a density of 5 × 10 3 cells/well. After 24 h, cells were washed with fresh medium, followed by treatment with SFN. After an incubation period of 48 h, cells were washed and 100 L of MTT (1 mg/mL) was added, followed by incubation for 4 h. Finally, DMSO (150 L) was added in order to solubilize the formazan salt formed, and the amount of formazan salt was determined by measuring the optical density (OD) at 540 nm using a microplate reader (Tecan Austria GmbH, Austria).
ELISA for TGFBIp:
TGFBIp concentrations in cell culture media or mouse serum were determined by competitive ELISA, as described previously [3, 6] . Ninety-six-well plastic flat microtiter plates (Corning, NY) were coated with TGFBIp protein in 20 mM carbonate-bicarbonate buffer (pH 9.6) with 0.02% sodium azide overnight at 4°C. Lyophilized culture media was pre-incubated with anti-TGFBIp antibodies in 96-well plastic round microtiter plates for 90 min at 37°C. Pre-incubated samples were transferred to a precoated plate and incubated for 30 min. After washing, the plates were incubated for 90 min with peroxidase-conjugated anti-rabbit IgG antibodies. The plates were incubated for 60 min at room temperature in the dark with 200 L substrate solution (100 g/mL o-phenylenediamine and 0.003% H 2 O 2 ). After stopping the reaction with 50 L of 8 N H 2 SO 4 , the absorbance was read at 490 nm.
ELISA for phosphorylated p38 MAPK:
The activity of phosphorylated p38 MAPK was quantified in accordance with the manufacturer's instructions using a commercially available ELISA kit (Cell Signaling Technology, Danvers, MA).
Permeability assay in vitro:
Permeability was quantitated by spectrophotometric measurement of the flux of Evans blue-bound albumin across functional HUVEC monolayers using a modified 2compartment chamber model, as previously described [6] . Briefly, HUVECs were plated (5 × 10 4 cells/well) in transwells with a pore size of 3 m and a diameter of 12-mm for three days. The confluent monolayers were treated with TGFBIp (5 g/mL for 6 h) followed by incubation with SFN for 6 h.
In vivo permeability and leukocyte migration assay:
For the in vivo study, male mice were anesthetized with 2% isoflurane (Forane, JW pharmaceutical, South Korea) in oxygen delivered via a small rodent gas anesthesia machine (RC2, Vetequip, Pleasanton, CA), first in a breathing chamber and then via a facemask. They were allowed to breath spontaneously during the procedure. Mice were treated with TGFBIp (0.1 mg/kg, i.v.) for 6 h followed by treatment with SFN (0.26 or 0.39 mg/kg) for 6 h. For the in vivo permeability assay [19] , 1% Evans blue dye solution in normal saline was injected intravenously into each mouse. Thirty minutes later, mice were euthanized and peritoneal exudates were collected by washing cavities with 5 mL of normal saline and centrifuging at 200g for 10 min. Absorbance of supernatants was read at 650 nm. Vascular permeabilities are expressed as g of dye/mouse that leaked into the peritoneal cavity and were determined using a standard curve, as previously described [20] . For assessment of leukocyte migration [19] , mice were euthanized after 6 h and peritoneal cavities were washed with 5 mL of normal saline. Samples (20 L) of peritoneal fluids obtained were mixed with 0.38 1630Natural Product Communications Vol. 12 (10) 2017 Lee & Bae mL of Turk's solution (0.01% crystal violet in 3% acetic acid), and the numbers of leukocytes were counted under a light microscope. Histopathological examination: Male C57BL/6 mice underwent CLP and were administered SFN (0.26 or 0.39 mg/kg) intravenously at 12 h and 50 h after CLP (n = 5). Mice were euthanized 96 h after CLP. To analyze the phenotypic changes in the mice lungs [19] , lung samples were removed from each mouse, washed three times in PBS (pH 7.4) to remove remaining blood, and fixed in 4% formaldehyde solution (Junsei, Tokyo, Japan) in PBS (pH 7.4) for 20 h at 4°C. After fixation, the samples were dehydrated through a series of ethanol, embedded in paraffin, sectioned at 4 μm thickness, and placed on a slide. The slides were deparaffinized in a 60°C oven, rehydrated, and stained with hematoxylin (Sigma). To remove over-staining, the slides were quickly dipped three times in 0.3% acid alcohol and counterstained with eosin (Sigma). The excess stain was removed using a series of ethanol and xylene, and coverslips were placed on the slides. Light microscopic analyses of lung specimens were performed by blinded observation to evaluate pulmonary architecture, tissue edema, and infiltration of the inflammatory cells as previously defined [21] . The results were classified into four grades where Grade 1 represented normal histopathology; Grade 2 indicated minimal neutrophil leukocyte infiltration; Grade 3 represented moderate neutrophil leukocyte infiltration, perivascular edema formation, and partial destruction of pulmonary architecture, and finally Grade 4 included dense neutrophil leukocyte infiltration, abscess formation, and complete destruction of pulmonary architecture.
Statistical analyses:
All experiments were independently performed a minimum of three times. Values were expressed as the mean ± standard deviation (SD). The statistical significance of differences between test groups was evaluated by SPSS for Windows, version 16.0 (SPSS, Chicago, IL). Statistical relevance was determined by one-way analysis of variance (ANOVA) and Tukey's post-test. Values of p < 0.05 were considered to indicate statistical significance. The survival of CLP-induced sepsis outcomes was assessed using Kaplan-Meier analysis.
